The therapeutic effects of WSY-0702 on benign prostatic hyperplasia in RWPE- 1

Abstract Background Benign prostatic hyperplasia (BPH) is a common disease which causes various health problems for elderly men such as urinary retention, recurring urinary tract infection and bladder stones. The aim of this study is to evaluate the therapeutic effects of Juniperus communis L. seed extract (JCS) on BPH in male Wistar rats. Methods To this end, 30 rats were divided into 5 groups (N = 6): group 1 (vehicle), group 2 (disease control), group 3 (standard medicine; 10 mg/kg finasteride), and groups 4 and 5 were treated with 300 mg/kg and 600 mg/kg of the hydroalcoholic JCS seed extract, respectively. Groups 2, 3, 4 and 5 received testosterone enanthate to induce prostatic hyperplasia. At the end of experimental period (28 days), prostate glands were cut off under anesthesia. Histopathological examination was done and biochemical parameters such as Malondialdehyde, Glutathione and protein carbonyl were also measured. Their body weights were also observed during the study. At the end of the experiment, prostate weights and prostate specific antigen (PSA) levels were measured. Prostate index, inhibition prostate weight and inhibition prostate index were also calculated. Results Both histopathological examination and biochemical parameter results showed significant improvements in rats treated with finasteride and 600 mg/kg JCS extract (p < 0.01). In addition, PSA levels showed significant decrease in comparison with the disease group. But acute toxicity test indicated that using JCS extract resulted in an increase in liver enzymes (ALP, LDH, SGOT, SGPT). As a result, the extract should be used with caution. Conclusions Oral administration of JCS extract is effective on preventing testosterone-induced benign prostatic hyperplasia.

Download Full-text

Therapeutic Effects of 25-Hydroxyvitamin D on the Pathological Process of Benign Prostatic Hyperplasia: An In Vitro Evidence

Disease Markers ◽

10.1155/2021/4029470 ◽

2021 ◽

Vol 2021 ◽

pp. 1-12

Author(s):

Yanbo Chen ◽

Hui Xu ◽

Chong Liu ◽

Meng Gu ◽

Qi Chen ◽

...

Keyword(s):

Oxidative Stress ◽

Vitamin D ◽

Benign Prostatic Hyperplasia ◽

Prostatic Hyperplasia ◽

Therapeutic Effects ◽

Prostate Cell ◽

Mesenchymal Transition ◽

Hydroxyvitamin D ◽

25 Hydroxyvitamin D

The pathogenesis of benign prostatic hyperplasia (BPH) is extremely complicated which involving the multiple signaling pathways. The deficiency of vitamin D is an important risk factor for BPH, and exogenous vitamin D is effective for the treatment of BPH. In this study, we provided in vitro mechanical evidence of vitamin D as a treatment for BPH using BPH-1, WPMY-1, and PBMC cells. We found that 25-hydroxyvitamin D (25-OH D) level is decreased in BPH and closely correlated with age, prostate volume, maximum flow, international prostate symptom score, and prostate-specific antigen of the BPH patients. We further revealed that 25-OH D ameliorated TGF-β1 induces epithelial-mesenchymal transition (EMT) of BPH-1 cells and proliferation of WPMY-1 cells via blocking TGF-β signaling. Moreover, 25-OH D was able to block NF-κB signaling in PBMCs of BPH patients and STAT3 signaling in BPH cells to relieve inflammation. 25-OH D also protects BPH cells from inflammatory cytokines selected by PBMCs. Finally, we uncovered that 25-OH D alleviated prostate cell oxidative stress by triggering Nrf2 signaling. In conclusion, our data verified that 25-OH D regulated multiple singling pathways to restrain prostate cell EMT, proliferation, inflammation, and oxidative stress. Our study provides in vitro mechanical evidence to support clinical use of vitamin D as a treatment for BPH.

Download Full-text

A STUDY ON INTERNATIONAL PROSTATE SYMPTOM SCORE IN THE ASSESSMENT OF THERAPEUTIC EFFECTS AND SEVERITY OF SYMPTOMS DUE TO BENIGN PROSTATIC HYPERPLASIA

The Japanese Journal of Urology ◽

10.5980/jpnjurol1989.86.1466 ◽

1995 ◽

Vol 86 (9) ◽

pp. 1466-1474 ◽

Cited By ~ 1

Author(s):

Eijiro Okajima ◽

Seiichiro Ozono ◽

Masahiko Ota ◽

Masahiro Tanaka ◽

Mitsuru Tani ◽

...

Keyword(s):

Benign Prostatic Hyperplasia ◽

Symptom Score ◽

International Prostate Symptom Score ◽

Prostatic Hyperplasia ◽

Therapeutic Effects

Download Full-text

Potential Therapeutic Effects of Underground Parts ofKalanchoe gastonis-bonnierion Benign Prostatic Hyperplasia

Evidence-based Complementary and Alternative Medicine ◽

10.1155/2019/6340757 ◽

2019 ◽

Vol 2019 ◽

pp. 1-10 ◽

Cited By ~ 1

Author(s):

Antonio Palumbo ◽

Livia Marques Casanova ◽

Maria Fernanda Paresqui Corrêa ◽

Nathalia Meireles Da Costa ◽

Luiz Eurico Nasciutti ◽

...

Keyword(s):

Benign Prostatic Hyperplasia ◽

Stromal Cells ◽

Prostate Gland ◽

Herbal Medicines ◽

Syringic Acid ◽

Pharmacological Therapy ◽

Prostatic Hyperplasia ◽

Therapeutic Effects ◽

Complex Chemical Composition ◽

Old Men

Benign Prostatic Hyperplasia (BPH) affects mainly older men. It is estimated to affect 50% of 51-60-year-old men and 70% of 61-70-year-old men. BPH is a nonmalignant proliferation of epithelial and stromal cells of the prostate gland regions. Despite the use of conventional pharmacological therapy, herbal medicines are used in BPH therapy, and several mechanisms of action have been suggested based on their complex chemical composition. Considering the ethnomedicinal uses ofKalanchoe gastonis-bonnieri(KGB), we evaluated the inhibitory effects on the proliferation of stromal cells from primary benign prostatic hyperplasia (BPH) of four different aqueous extracts from this plant: underground parts from specimens in flower (T1 treatment), leaves from specimens in flower (T2 treatment), and flowers (T3 treatment) and leaves from specimens not in flower (T4 treatment). T1, T2, T3, and T4 treatments at 250μg/ml for 72 hours inhibited BPH cells by 56.7%, 29.2%, 39.4%, and 13.5%, respectively, showing that the KGB underground parts extract (T1 treatment) was the most active. Our findings show that the extract of the KGB underground parts (150 and 250μg/ml) stimulates important changes in the BPH cells, modulating crucial processes such as proliferation, viability, and apoptosis. HPLC-DAD-MS/MS analysis provided a tentative identification of glycosylated syringic acid derivatives, glycosylated forms of volatile compounds, and lignans in this extract. Finally, these results suggest that there is a potential therapeutic use for KGB in BPH, which could improve the clinical management of the disease.

Download Full-text

Therapeutic effects of add-on botulinum toxin A on patients with large benign prostatic hyperplasia and unsatisfactory response to combined medical therapy

Scandinavian Journal of Urology and Nephrology ◽

10.1080/00365590902811537 ◽

2009 ◽

Vol 43 (3) ◽

pp. 206-211 ◽

Cited By ~ 28

Author(s):

Hann-Chorng Kuo ◽

Hsin-Tzu Liu

Keyword(s):

Botulinum Toxin ◽

Benign Prostatic Hyperplasia ◽

Medical Therapy ◽

Botulinum Toxin A ◽

Prostatic Hyperplasia ◽

Therapeutic Effects ◽

Toxin A

Download Full-text

6′-Sialyllactose Ameliorates in Vivo and in Vitro Benign Prostatic Hyperplasia by Regulating the E2F1/pRb–AR Pathway

Nutrients ◽

10.3390/nu11092203 ◽

2019 ◽

Vol 11 (9) ◽

pp. 2203 ◽

Cited By ~ 2

Author(s):

Jin ◽

Kim ◽

Chung ◽

Ha ◽

...

Keyword(s):

Cell Cycle ◽

Benign Prostatic Hyperplasia ◽

Specific Antigen ◽

Prostatic Hyperplasia ◽

Control Group ◽

Therapeutic Effects ◽

Cell Cycle Protein ◽

Wide Range

Abstract: Background: 6′-Sialyllactose (6SL) displays a wide range of the bioactive benefits, such as anti-proliferative and anti-angiogenic activities. However, the therapeutic effects of 6SL on benign prostatic hyperplasia (BPH) remain unknown. Methods: Six-week-old male Wistar rats (n = 40) were used for in vivo experiments. All rats were castrated and experimental BPH was induced in castrated rats by intramuscular injection of testosterone, with the exception of those in the control group. Rats with BPH were administrated finasteride and 0.5 or 1.0 mg/kg 6SL. Furthermore, the inhibitory effects of 6SL on human epithelial BPH cell line (BPH-1) cells were determined in vitro. Results: Rats with BPH exhibited outstanding BPH manifestations, including prostate enlargement, histological alterations, and increased prostate-specific antigen (PSA) levels. Compared to those in the BPH group, rats in the 6SL group showed fewer pathological changes and normal androgen events, followed by restoration of retinoblastoma protein (pRb) and cell cycle-related proteins. In BPH-1 cells, treatment with 6SL significantly suppressed the effects on the androgen receptor (AR), PSA, and E2F transcription factor 1 (E2F1)-dependent cell cycle protein expression. Conclusions: 6SL demonstrated anti-proliferative effects in a testosterone-induced BPH rat model and on BPH-1 cells by regulating the pRB/E2F1–AR pathway. According to our results, we suggest that 6SL may be considered a potential agent for the treatment of BPH.

Download Full-text